Engineered primate cystine/cysteine degrading enzymes as antineogenic agents

Patent metadata

Field	Value
Publication number	US-11426464-B2
Application number	US-202016929438-A
Country	US
Kind code	B2
Filing date	Jul 15, 2020
Priority date	Aug 29, 2013
Publication date	Aug 30, 2022
Grant date	Aug 30, 2022

Abstract

Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.

First claim

What is claimed is:

1. A method of treating a subject having a cancer, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation comprising (i) a variant of a native primate cystathionine-gamma-lyase (CGL) enzyme, wherein the variant CGL has cysteine/cystine degrading activity, wherein the variant CGL has a sequence at least 95% identical to SEQ ID NO: 1, and wherein the variant CGL comprises E59T and E339V substitutions relative to SEQ ID NO: 1 and (ii) a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the variant CGL has a sequence according to SEQ ID NO: 2.

3. The method of claim 1 , wherein the variant CGL further comprises a heterologous peptide segment.

4. The method of claim 1 , wherein the variant CGL is coupled to at least one polyethylene glycol (PEG).

5. The method of claim 4 , wherein the variant CGL is coupled to the at least one PEG via one or more lysine or cystine residues.

6. The method of claim 1 , wherein the subject is maintained on a L-cystine and/or L-cysteine restricted diet.

7. The method of claim 1 , wherein cancerous cells have been identified as having a decreased expression level of a cystathionine-β-synthase or cystathionine-γ-lyase gene relative to a non-cancer cell.

8. The method of claim 1 , wherein cancerous cells have been identified as having an increased expression level of a xCT(−) cysteine transporter relative to a non-cancer cell.

9. The method of claim 1 , wherein the formulation is administered intravenously, intradermally, intraarterially, intranodally, intrathecally, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intraocularly, intranasally, intravitreally, intravaginally, intrarectally, intramuscularly, subcutaneously, subconjunctival, intravesicularlly, mucosally, intrapericardially, intraumbilically, orally, by inhalation, by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, via a catheter, or via a lavage.

10. The method of claim 1 , further comprising administering a further anticancer therapy to the subject.

11. The method of claim 10 , wherein the further anticancer therapy is a surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormone therapy, immunotherapy or cytokine therapy.

12. A method of reducing cysteine levels and/or cystine levels in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical formulation comprising (i) a variant of a native primate cystathionine-gamma-lyase (CGL) enzyme, wherein the variant CGL has cysteine/cystine degrading activity, wherein the variant CGL has a sequence at least 95% identical to SEQ ID NO: 1, and wherein the variant CGL comprises E59T and E339V substitutions relative to SEQ ID NO: 1 and (ii) a pharmaceutically acceptable carrier, thereby reducing cysteine levels and/or cystine levels in the subject.

13. The method of claim 12 , wherein the variant CGL has a sequence according to SEQ ID NO: 2.

14. The method of claim 12 , wherein the variant CGL further comprises a heterologous peptide segment.

15. The method of claim 12 , wherein the variant CGL is coupled to at least one polyethylene glycol (PEG).

16. The method of claim 15 , wherein the variant CGL is coupled to the at least one PEG via one or more lysine or cystine residues.

17. The method of claim 12 , wherein the cysteine levels and/or cystine levels are serum cysteine levels and/or serum cystine levels.

18. The method of claim 12 , wherein the formulation is administered intravenously, intradermally, intraarterially, intranodally, intrathecally, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intraocularly, intranasally, intravitreally, intravaginally, intrarectally, intramuscularly, subcutaneously, subconjunctival, intravesicularlly, mucosally, intrapericardially, intraumbilically, orally, by inhalation, by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, via a catheter, or via a lavage.

Assignees

• Univ Texas

Inventors

• Georgiou George
• Stone Everett

Classifications

• A61K38/51 Primary

  Lyases (4) · CPC title

• C12N9/88 Primary

  Lyases (4.) · CPC title

• C12Y404/01001

  Cystathionine gamma-lyase (4.4.1.1) · CPC title

• C12N15/52

  Genes encoding for enzymes or proenzymes · CPC title

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title